



Investment Plan for Europe

Support for Growth

Jean-Christophe Laloux **Director General**

23 April 2015






Strong, continuous and steady support to Greece, notably during the crisis years

• Total EIB lending in Greece over the past 5 years: EUR 7.7 billion

• Total EIB lending in Greece in 2014: EUR 1.5 billion

• Total EIB exposure in Greece: EUR 17.2 billion

• Customised products: Trade Finance Facility
SME Guarantee Fund



FIB lending by sector in Greece from 2010 to 2014 (in EUR m)

■ Energy	23%
Transport, telecommunications	34%
Water, sewerage, solid waste, urban development	9%
Industry, services, agriculture	12 %
Education, health	6%
Small and medium-scale projects	16%







Pharmathen Case Study under InnovFin products

Transaction structure

■ Signature: November 2014

■ Amount: EUR 25m

Instrument: InnovFin MidCap Growth

Finance

Purpose: Finance the development and

production of pharmaceuticals

• Other: First InnovFin / RSFF loan in

Greece

EIB Investment rationale

- Innovative midcap pharmaceutical company, with proven expertise in drug development
- Strong sales growth and increase in people employed in recent years, despite Greek economic crisis
- Diversification of funding outside of Greek banks


Borrower Profile

- Family owned pharmaceutical company
- One of the largest Greek pharmaceutical companies
- Focused on B2B sales of generic drugs






Every piece of the puzzle counts







Mobilising New Investment







Instruments to be deployed (WORK IN PROGRESS)

INNOVATION

GUARANTEEs for SMEs

INFRASTRUCTURE

VENTURE CAPITAL for SMEs and midcaps

EQUITY-TYPE

Some of the initiatives in collaboration with other public, promotional institutions

